BPC-157 vs Ipamorelin: Healing Peptide vs GH Secretagogue Comparison | Peptpedia
This comprehensive analysis compares BPC-157 and Ipamorelin based on peer-reviewed clinical research, examining their mechanisms of action, efficacy data, and safety profiles. For complete individual peptide profiles, visit the dedicated research pages linked above.
BPC-157 and Ipamorelin target entirely different physiological systems: BPC-157 is a tissue repair peptide derived from gastric juice that promotes healing through angiogenesis and fibroblast activation; Ipamorelin is a selective GHRP that stimulates pituitary GH release. They are frequently combined in research stacks because their non-overlapping mechanisms make them theoretically complementary—Ipamorelin's GH/IGF-1 axis stimulation supports muscle repair and recovery, while BPC-157 promotes direct tissue healing at injury sites.
Chemical Identity
Side-by-Side Comparison
| Property | BPC-157 | Ipamorelin |
|---|---|---|
| Primary Effect | Tissue repair, angiogenesis, gut healing | GH pulse stimulation, body composition |
| Mechanism | FAK-paxillin, NO modulation, VEGF upregulation | GHSR-1a ghrelin receptor agonism |
| Target Tissue | Tendon, muscle, gut mucosa, skin | Pituitary gland (GH secretion) |
| Off-target Effects | Anti-inflammatory, cytoprotective | None significant (highly selective GHRP) |
| Research Status | Preclinical; no human RCTs | Preclinical; no FDA approval |
| Half-Life | ~4 hours (IP injection) | ~2 hours |
| Common Stack Use | Often combined with TB-500 or GHRPs | Often combined with GHRH analogs (CJC-1295) |
Mechanism: Tissue Repair vs GH Secretion
BPC-157 promotes tissue repair through several converging mechanisms. It upregulates growth hormone receptors on fibroblasts (amplifying local healing responses), activates the FAK-paxillin pathway (promoting cell adhesion and migration into damaged tissue), modulates nitric oxide synthesis (improving local blood flow), and activates the Egr-1/NAB2 transcription loop (driving organized angiogenesis at wound sites). These direct tissue-level effects are independent of systemic hormone levels.
Ipamorelin acts centrally by activating the GHSR-1a ghrelin receptor on pituitary somatotrophs, amplifying GH pulse amplitude without stimulating cortisol, prolactin, or ACTH release (unlike less selective GHRPs). Elevated GH levels then trigger hepatic IGF-1 production, which drives systemic anabolic and recovery-promoting effects including protein synthesis, lipolysis, and connective tissue support.
Frequently Asked Questions
Research Citations
Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157
Sikiric P, Seiwerth S, Rucman R, et al. (2012). Current Medicinal Chemistry